CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
September 13, 2024
2024年9月13日
Berkeley Heights, NJ – September 13, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
新澤西州伯克利高地——2024年9月13日——專注於開發和商業化用於預防和治療危及生命的疾病的治療產品的生物製藥公司CorMedix公司（納斯達克股票代碼：CRMD）今天宣佈，管理層將參加2024年9月17日至19日在紐約州紐約舉行的2024年坎託醫療會議的爐邊談話和投資者會議。
Cantor Global Healthcare Conference
Date: Thursday, September 19, 2024
Time: 10:55AM EDT
Format: Fireside Chat and 1×1 Meetings
Webcast: Click Link
Cantor 全球醫療保健會議
日期：2024 年 9 月 19 日星期四
時間：美國東部時間上午 10:55
形式：爐邊聊天和 1×1 會議
網絡直播：點擊鏈接
A replay of the fireside chat will also be available in the "Events and Presentations" page on the investor relations portion of the Company's website at:
爐邊談話的重播也將在公司網站投資者關係部分的 「活動和演講」 頁面上播出，網址爲：
About CorMedix
關於 Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: .
CormediX Inc. 是一家生物製藥公司，專注於開發和商業化治療產品，用於預防和治療危及生命的疾病和疾病。該公司專注於將其主要產品DefenCath商業化，該產品於2023年11月15日獲得美國食品藥品管理局的批准。CorMedix 於 2024 年 4 月在住院環境中商業推出 DefenCath，並於 2024 年 7 月在門診環境中推出。CorMedix還打算開發DefenCath作爲導管鎖解決方案，用於其他患者群體。欲了解更多信息，請訪問:.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投資者聯繫人：
丹·費裏
董事總經理
生命科學顧問
daniel@lifesciadvisors.com
(617) 430-7576
譯文內容由第三人軟體翻譯。